Avalon Trust’s VanEck Pharmaceutical ETF PPH Stock Holding History

Avalon Trust’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.8M	Sell	263,830 -3,870	-1%	-$401K	1.77%	14
2026 Q1	$27.8M	Sell	267,700 -154	-0.1%	-$16.4K	1.92%	13
2025 Q4	$27.6M	Sell	267,854 -7,546	-3%	-$734K	1.79%	14
2025 Q3	$24.9M	Sell	275,400 -5,077	-2%	-$445K	1.62%	18
2025 Q2	$24.7M	Sell	280,477 -3,208	-1%	-$278K	1.8%	13
2025 Q1	$25.9M	Buy	283,685 +895	+0.3%	+$80.6K	2.06%	12
2024 Q4	$24.4M	Sell	282,790 -5	-0%	-$452	1.74%	17
2024 Q3	$26.9M	Sell	282,795 -2,180	-0.8%	-$207K	1.99%	15
2024 Q2	$26.1M	Buy	284,975 +100	+0%	+$8.93K	2.06%	13
2024 Q1	$25.8M	Sell	284,875 -500	-0.2%	-$43.8K	2.12%	12
2023 Q4	$23.2M	Sell	285,375 -2,200	-0.8%	-$173K	2.12%	14
2023 Q3	$23M	Buy	287,575 +1,350	+0.5%	+$109K	2.27%	12
2023 Q2	$22.5M	Sell	286,225 -150	-0.1%	-$11.7K	2.04%	14
2023 Q1	$22.2M	Buy	+286,375	New	+$22.1M	2.2%	14

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Avalon Trust's PPH Position: Q2 2026 in Review

Avalon Trust reduced its VanEck Pharmaceutical ETF (PPH) stake by 1.4% in Q2 2026, selling an estimated $401K and leaving 263,830 shares worth $28.8M. The position accounts for 1.77% of the portfolio, ranked #14.

Avalon Trust first reported a position in PPH in Q1 2023 and has held it in 14 quarters since. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Avalon Trust held 263,830 shares of VanEck Pharmaceutical ETF worth $28.8M as of Q2 2026.
Avalon Trust sold 3,870 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $401K.
VanEck Pharmaceutical ETF made up 1.77% of Avalon Trust's portfolio in Q2 2026, its #14 holding.
Avalon Trust first reported a position in VanEck Pharmaceutical ETF in Q1 2023 and has held it in 14 quarters since.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Avalon Trust's 13F filing for Q2 2026, filed 6 Aug 2026.